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Summary 
C.B-17 scid/scid (severe combined immunodeficiency [SCID]) mice inoculated with peripheral 
blood lymphocytes from Epstein-Barr virus  (EBV)-seropositive donors, or with EBV-trans- 
formed lymphoblastoid B  cell lines (EBV-LCL), develop lethal human EBV  + B  cell lympho- 
proliferative disorders (EBV-LPD) with characteristics similar to those arising in immunodefi- 
cient patients. Using this model, we examined the capacity of human effector cells to control 
human EBV-LPD. SCID mice received rabbit anti-asialo GM1 antiserum to abrogate endoge- 
nous natural killer-cell function. Prehminary experiments showed that adoptive transfer of pe- 
ripheral blood mononuclear cells (PBMC), purified T  cells, interleukin (IL) 2-activated PBMC 
or anti-CD3-activated T  cells  derived from EBV-seropositive donors did not result in im- 
proved survival of treated mice (in vivo effector/target ratio 2:1 to 1:1). In contrast, EBV-spe- 
cific cytotoxic T lymphocytes (CTL), derived from EBV-seropositive donors and expanded in 
vitro,  exhibited strong EBV-specific and HLA-restricted activity both in vitro and in vivo. 
SCID mice inoculated intraperitoneally with autologous but not with HLA-mismatched EBV- 
LCL had significantly improved survival relative to untreated mice after inoculation of EBV- 
specific CTL either intraperitoneally (P <0.001) or intravenously (P <0.001) (in vivo effector/ 
target ratio  1:1).  SCID  mice bearing large subcutaneous EBV  +  tumors  and treated intrave- 
nously with  107  EBV-specific  CTL  achieved  complete  tumor  regression.  Both  CTL-  and 
CTL-plus-IL-2-treated mice survived significantly longer than untreated animals  or animals 
treated with IL-2 alone (P =  0.004 and P <0.02, respectively). SCID mice bearing two subcu- 
taneous EBV  + tumors, one autologous and the other HLA mismatched to the EBV-specific 
CTL donor, had regression of only the  autologous tumor after intravenous infusion of 107 
EBV-specific CTL. Moreover, we could demonstrate preferential homing of PKH26-1abeled 
EBV-specific CTL to autologous but not to HLA-mismatched EBV  + tumors as early as 24 h 
after intravenous adoptive transfer. Immunophenotypic analyses also demonstrated preferential 
infiltration of T  cells into the autologous EBV  + tumor in SCID mice bearing both the au- 
tologous and either fully HLA-mismatched or genotypically related haplotype-sharing EBV  § 
tumors.  The  human  T  cells  infiltrating  EBV  +  tumors  were  CD3 +  and,  predominantly, 
CD8+CD4 -.  Our results  indicate that EBV-specific CTL preferentially localize to and infil- 
trate EBV  § tumors bearing the appropriate HLA antigens and thereafter induce targeted regres- 
sions of disease. 
E 
BV is a ubiquitous human herpesvirus that latently in- 
fects B cells of most of individuals by adulthood (1, 2). 
Persistent  infection  usually  has  no  clinical  consequences 
among immunocompetent individuals.  However, patients 
with  severe  congenital  or  acquired  deficiencies  of cell- 
mediated  immunity  are  at  increased  risk  for  developing 
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LPD) 1 (1,  2).  In organ allograft recipients,  these  disorders 
tend  to  be  polyctonal,  of either  donor or host  origin,  and 
may regress  spontaneously when  administration  of immu- 
nosuppressive  drugs  is  curtailed  (2,  3).  In  contrast,  bone 
marrow transplant  (BMT) patients frequently present either 
with oligoclonal or monoclonal disorders, which are almost 
unifomdy refractory to treatment with antineoplastic or an- 
tiviral drugs (2,  4-7). 
The possibility of transferring resistance to virus-induced 
tumors by adoptive cell therapy has been demonstrated in 
murine models (8).  In 1992, Pdddell et al.  (9)  also showed 
that adoptive transfer of CMV-specific T  cell clones could 
restore anti-CMV immunity in human BMT recipients. More 
recently, we have reported a series of five patients  that de- 
veloped EBV-LPD  of donor B  cell  origin after  a  T  cell- 
depleted BMT who achieved durable complete remissions 
after infusions of PBMC derived tiom their EBV-seropositive 
bone marrow donor (10). In formulating this approach, we 
reasoned that EBV-specific T  cells,  which circulate at high 
frequency in EBV-seropositive  individuals  (11),  might be 
able to multiply in the EBV + lymphoma-bearing BMT re- 
cipient and induce regressions of  disease. Indeed, we have sub- 
sequently shown that these donor PBMC infusions induced 
a marked increase in the number ofEBV-specific cytotoxic 
T  cell precursors (CTLp) in the circulation (12). In addition, 
Servida et al.  (13) and R.ooney et al. (14) have demonstrated 
regressions of EBV-LPD in BMT recipients after infusions 
of  in vitro-generated EBV-specific T lymphocytes, again im- 
plicating these cells as the effectors of  the regressions observed. 
Mutant C.B-17 mice homozygous for the autosomal re- 
cessive mutation scid  (SCID mice) are severely deficient in 
B and T  lymphocytes (15,  16). However, SCID mice have 
normal myeloid, APC, and NK cell function (17-19).  Be- 
cause of their inability to generate functional lymphocytes, 
SCID mice are permissive to the engraftment and growth of 
human lymphocytes and several human tumors (19-21). Hu- 
man  lymphocytes have  also  been  shown  to  remain  func- 
tional in the SCID mouse after adoptive transfer (21). Inoc- 
ulation  of SCID  mice  with  PBL  from EBV-seropositive 
donors or with EBV-transformed lymphoblastoid cell lines 
(EBV-LCL) results in the development ofEBV-induced im- 
munoblastic B  cell lymphomas with characteristics similar to 
EBV-LPD arising in immunocompromised hosts (20, 22, 23). 
Based  on these  observations,  we  hypothesized that  this 
animal model might provide an informative system for eval- 
uating the antilymphoma activity of different human effec- 
tor cell populations. Accordingly, we have established both 
intraperitoneal  and subcutaneous models for the growth of 
human EBV-LPD in SCID mice to examine the effects of  in- 
fusions of different types of human effector cells. These studies 
demonstrate that in vitro-expanded EBV-specific T  cells, de- 
'Abbreviations used in  this paper: o~-asialo GM1, anti-asialo GM1 antiserttm; 
BMT, bone marrow transplant; CM,  complete medium; CTLp, CTL 
precursor; EBV-LCL,  EBV-transformed lymphoblastoid  B cell line; EBV- 
LPD, EBV-induced B cell lymphoproliferative  disorder; SL, specific lysis; 
TIE, tumor infiltrating lymphocytes. 
rived from normal EBV-seropositive individuals,  can induce 
regressions of autologous but not of HLA-mismatched hu- 
man EBV-LPD when administered intraperitoneaUy or in- 
travenously into tumor-bearing mice. Moreover, using su- 
pravital labeling techniques and immunophenotyping studies, 
we could show preferential homing and infiltration of EBV- 
specific T  lymphocytes into autologous subcutaneous tumors 
in  animals  bearing both  autologous and  either  HLA-mis- 
matched  or genotypically related  haplotype-sharing HLA- 
matched EBV + tumors. 
Materials  and Methods 
Mice.  5-8-wk-old  C.B-17  scid/scid  mice,  purchased  from 
Taconic Farms, Inc. (Germantown, NY), were maintained in mi- 
croisolater  cages (three  to five per cage) under specific pathogen- 
free conditions. Mice received autoclaved food and water.  Inves- 
tigators handling the mice wore gloves, mask, cap, and gown, and 
all animal  manipulations were performed in a laminar  flow hood 
in the same room. Procedures were reviewed and approved by 
the Institutional  Animal Care and Use Committee. 
Tumor Cell Lines.  EBV-LCL were established by infection of 
PBL or purified B cells from EBV-seropositive donors with su- 
pematants  from the  EBV-secreting marmoset  cell  line,  B95-8, 
and  were  propagated  in  RPMI  1640  supplemented  with  15% 
heat-inactivated fetal bovine serum  (FBS), L-glutamine,  sodium 
pyruvate, penicillin  and streptomycin, essential and nonessential 
amino acids, and anti-PPLO agent (all purchased  from Gibco Lab- 
oratories,  Grand Island, NY). All cell lines were mycoplasma free. 
Effector Cells.  PBMC,  purified  B  and T  cells, were  isolated 
from heparinized peripheral  blood of healthy EBV-seropositive 
individuals,  following standard  techniques.  Briefly,  after gradient 
centrifugation  over Ficoll-Hypaque  (density  1.077  g/ml)  (Ny- 
comed,  Oslo,  Norway),  mononuclear  cells were  suspended  in 
RPMI 1640 supplemented with 10% heat-inactivated human se- 
rum  (W'hittaker  Bioproducts,  Walkersville,  MD),  t-glutamine, 
penicillin  and streptomycin, essential and nonessential  amino ac- 
ids, sodium pyruvate, and anti-PPLO agent (hereafter  referred  to 
as complete medium  [CM])  and allowed to adhere  over plastic 
surfaces for 2 h at 37~  and 5% CO2.  Nonadherent cells (PBL) 
were  thereafter separated  by differential  rosette  formation with 
SRBC (Colorado Serum Co., Denver, CO) into E + (T cell frac- 
tion) and E  cells. 
For the generation of IL-2-activated PBMC, 2.5  X  106 cells/ 
ml were incubated for 72 h with 500 IU/ml of hrlL-2 (Becton 
Dickinson,  Collaborative  Biomedical  Products,  Bedford,  MA). 
To obtain nonspecifically  activated T cells, aliquots of 106/ml pu- 
rified  T  cells were stimulated  with 20  I~g/ml biotin-conjugated 
anti-CD3 mAb (Becton Dickinson & Co., San Jose, CA) at room 
temperature for 30 rain,  washed once in RPMI 1640 to remove 
unbound antibody, and incubated in CM with  10 ~g/ml avidin 
(Pierce  Chemical Co.,  Rockford, IL) to cross-link  bound anti- 
CD3 mAb for 72 h, in the presence  of 5 X 10S/ml autologous ir- 
radiated  (3,000 rad) PBMC. 
For the generation of EBV-specific  CTL, standard  stimulation 
techniques were used (11). Briefly,  purified T  cells (E  + cells) in 
CM were incubated in 24-well plates (Costar  Corp., Cambridge, 
MA), at a final concentration of 2 ￿  106 cells/well,  with 5 ￿  104 
irradiated  (9,000 rad) autologous EBV-LCL as stimulator  cells and 
106 irradiated  (3,000  rad) autologous PBMC as feeder cells. On 
days 3, 6, and 9, each well received 1 ml of CM containing 10-20 
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plates (1.5-2 X 106/well) in the presence  of irradiated autologous 
EBV-LCL (responder/stimulator ratio  =  5:1) and 106 irradiated 
autologous PBMC. Thereafter,  cultures were fed every 3-4 d with 
CM containing 10  IU/ml IL-2 and restimulated weekly at the 
same cell concentration  with irradiated autologous EBV-LCL and 
PBMC. 1<esponding cells were used for in vivo experiments after 
26 or 33  d in culture (i.e., inoculated the day after the third or 
fourth restimulation with autologous EBV-LCL, respectively). 
In Vivo Studies.  SCID mice were treated intraperitoneally with 
30  Ixl rabbit anti-asialo  GM1  antiserum (ot-asialo GM1)  (Wako 
Bioproducts, Richmond, VA) on days -1, 4, 8, and every 5-7 d 
thereafter  for the duration of the study, for depletion of endoge- 
nous NK cell function (24), as described in detail elsewhere  (25). 
The effector cells were administered either by the intraperitoneal 
or intravenous route at doses and times after EBV-LCL inocula- 
tion also specified in the presentation of results. Animals treated 
with IL-2 received 2,500  IU i.p. twice dally for 14 d, starting on 
the day of adoptive immunotherapy (first dose administered 4-6 h 
before CTL inoculation), unless otherwise  specified. SCID mice 
were observed twice weekly for development of signs of disease 
(loss of activity, weight loss, ruffled hair, palpable tumors, ascites). 
Moribund animals were killed by cervical dislocation.  Otherwise, 
SCID mice were followed for 30 wk and then killed. 
Cytotoxicity Assays.  Cytotoxicity of the responding T cells was 
assessed using standard  4-h chromium release assays. Target cells 
included the  autologous EBV-LCL,  EBV-LCL  sharing one  or 
more HLA class I and/or class II antigens with autologous EBV- 
LCL,  fully HLA-mismatched EBV-LCL, autologous EBV- acti- 
vated B cells (stimulated with 10 ng/ml PMA and 1 I.tM/ml ion- 
omycin), and the NK-sensitive erythroleukemia cell line K562. 
Target and effector  cells were incubated in CM at various  E/T 
ratios, as indicated, in round-bottom 96-well plates (Costar Corp.), 
at 37~  and 5% CO2. After 4 h, supernatants  were harvested  and 
counted for  1 rain. Spontaneous release was <15% of maximal 
51Cr release. The percentage of specific lysis (SL) was determined 
by the following equation: [experimental SlCr release  (cpm)  - 
spontaneous SlCr release  (cpm)]/[maximal SlCr release (cpm)  - 
sPontaneous SlCr release (cpm)] ￿  100. In all cytotoxicity exper- 
iments, data are presented as mean SL oftriphcate  cultures performed 
for each E/T ratio. 
For the experiments shown in Fig. 3, the indicated concentra- 
tions ofanti-HLA-A,B,C (clone G46-2.6), anti-HLA-DR,DP,DQ 
(clone Tii36) (both purchased from PharMingen, San Diego, CA), 
anti-CD3  (clone SK-7)  (Becton Dickinson &  Co.),  and anti- 
TCR. c~/[3 (clone  WT-31) (Collaborative  Biomedical Products) 
mAb were incubated for 1 h at 37~  in 5% CO  2 either with the 
target  cells (anti-HLA class I  and II mAb) or with the  effector 
cells (anti-CD3 and TCP,-c~/{3 mAb) before the 4-h coincuba- 
tion period. 
The frequency of donor EBV-specific CTLp was assessed by 
limiting dilution analysis using a modification of techniques pre- 
viously described  (11, 12). Briefly, purified T cells were plated in 
limiting twofold dilutions in the presence of 2.5  ￿  104 autolo- 
gous EBV-LCL and 2 ￿  103 autologous irradiated PBMC in 96- 
well round-bottom plates  (Costar  Corp.)  and fed  on days 3,  6, 
and 9 with 50 btl CM containing 10 IU/ml IL-2.24 replicates for 
each dilution were used. At days 11-13, each CTL culture was split 
into four replicates and evaluated as effectors in standard 4-h SlCr 
release assays against autologous EBV- activated  B cells, autolo- 
gous EBV-LCL, a mismatched EBV-LCL, and K562. Wells were 
scored positive when the percentage of SL exceeded 8-10% (11). 
95% confidence limits are presented. 
Histopathology and Immunohistochemistry.  Samples  of tumors and 
organs to be analyzed were fixed in 10% formalin or a 3% mercu- 
ric chloride in 4% formaldehyde solution, embedded in paraffin, 
sectioned, and stained with hematoxylin and eosin.  Snap frozen 
sections in OCT medium (Diagnostics Division, Elkhart,  Indiana) 
were also stained with hematoxylin and eosin. Antibodies used 
in  immunohistochemistry studies  included mouse  anti-human 
CD20  mAb  (L26 clone),  mouse  anti-human K  (R.10-21-F3 
clone) and ~. (N10/2 clone) Ig light chain mAb, and mouse anti- 
human  CD45R.O  mAb  (UCHL1  clone),  all  purchased  from 
Dako Corporation (Carpinteria,  CA). 
Flow Cytometry.  EBV-LCL, purified T cells, in vitro-cultured 
EBV-specific  T  cells, and single-cell suspensions  obtained from 
tumor-bearing animals were  stained with  FITC- or PE-conju- 
gated mAb directed against the following human antigens: CD 19, 
CD20, CD11a, CD18, CD54, CD11b, CDllc, CD44, CD49d, 
CD80,  CD3,  CD4,  CD8,  CD25,  HLA-DR,  CD16/CD56, 
CD45RO,  CD45RA,  and  CD45  (all purchased  from  Becton 
Dickinson & Co.), and CD58 (Amac Inc., Westbrook, ME). Iso- 
type controls were purchased from Becton Dickinson & Co. Mouse 
cells were detected by anti-mouse CD45 FITC-conjugated mAb 
(Boehringer Mannheim Corp., Indianapolis,  IN). Viable  cells in 
single-cell  suspensions  derived from tumors were  isolated  after 
gradient centrifugation over Ficoll-Hypaque. Before the addition 
of staining antibodies, single cell suspensions of tumors were incu- 
bated  with  1  ~g  purified  rat  anti-mouse  CD32/CD16  mAb 
(PharMingen)  at room temperature for 10 min, to prevent non- 
specific  Fc  receptor-mediated binding of staining antibodies to 
mouse cells. Samples of both the in vitro-cultured EBV-LCL and 
EBV-specific  CTL inoculated into SCID mice were used for in- 
strument setup before analysis of tumor single-cell suspensions. 
A FACScan  |  flow cytometer using LYSIS II software (Becton 
Dickinson & Co.) in the Institution's Flow Cytometry Core Fa- 
cility was used for analysis of surface antigen expression. 
In Situ Hybffdization.  Fluorescence in situ hybridization of sin- 
gle-cell suspensions from tumors and mouse organs to detect hu- 
man X and Y chromosomes (probes purchased from Oncor Inc., 
Gaithersburg,  MD),  was  performed  using standard  techniques, 
described  in detail  elsewhere  (25). For  the  detection of small 
EBV-encoded RNAs  (EBEP,-1  and EBER-2),  complementary 
deoxyribooligonucleotide probes  (Dako  Corp.)  were  used  ac- 
cording to the manufacturer's protocols (26). 
Southern Blotting.  Southern blots  of genomic DNA digested 
with EcoKl, HindlII, or BamHI were performed on a semiauto- 
mated blotting system  (Probe Tech II; Oncor Corp.),  as previ- 
ously described  (10). Placental DNA was used as germline, nor- 
real control. The probes used included a 5.6-kb HindlII-BamHI 
fragment spanning the entire J region of the Ig H  chain gene and 
a 1.9-kb XhoI fragment adjacent to the terminal repeats of EBV 
DNA for detection of clonality and linearization of EBV DNA. 
For the MYC gene, DNA was digested  with EcoR.I  or HindlII 
and probed with the XhoI-Xbal fragment of the first exon. 
In Vivo Tracking with PKH26-1abeled EBV-specific CTL.  EBV- 
specific CTL were harvested, washed twice in HBSS without cal- 
cium or magnesium, counted, and stained with PKH26  (Sigma 
Chemical Co.,  St. Louis,  MO)  according to the manufacturer's 
instructions (27). Briefly, washed cells were resuspended in dilu- 
ent C, after which they were immediately added to an equal vol- 
ume of a  10-},M  PKH26 solution in diluent C.  Final cell con- 
centration was  1.6  X  106 cells/mE  The cells were incubated at 
room temperature for 2  rain, after  which the  staining reaction 
was stopped by the addition of an equal volume of pure FBS. 
Thereafter,  the cells were washed  three times in CM (10% FBS 
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into animals bearing subcutaneous EBV  + lymphomas. After 24 h, 
the animals were killed, tumor sections were snap frozen in OCT, 
and cryostat sections were  analyzed by fluorescence  microscopy 
in a fluorescence microscope (HEX-II; Nikon Inc., Garden City, 
NY) with filter combinations for rhodamine. 
Statistical Analysis.  The Wilcoxon rank-sum test was  used to 
compare the survival of SCID  mice  treated with CTL  alone or 
CTL  plus  IL-2,  relative to  untreated animals or animals treated 
with IL-2 alone, respectively. 
Results 
Features of  Human EB V + Tumors in SCID Mice.  We  char- 
acterized  the  lymphomas  developing  in  SCID  mice  after 
Figure 1.  Characteristics  of human EBV-LPD in the SCID mouse.  (a) Subcutaneous human EBV-LPD infiltrating skeletal muscle in the SCID mouse. 
These lymphomas were classified as immunoblastic lymphomas, often with plasmacytoid  features  (hematoxyhn and eosin)  ￿  (b) The lymphoma cells 
were CD20 + ￿  (c) The arising tumors were clonal, denoted in this case by absence of human Ig K L chain expression,  and (d) uniform positivity for 
human Ig k L chain mAb. ￿  (e) Fluorescence  in situ hybridization detected human X chromosome in the infiltrating tumor cells (e.g., male cells, one 
signal/cell).  ￿  (f) In situ hybridization detected small EBV-encoded RNAs (EBER-1 and EBEIL-2)  within the infiltrating cells (brown indusions). 
￿ 
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as to their pathologic and immunophenotypic features, pat- 
tern of dissemination, and molecular characteristics. Histo- 
logically, these EBV-LPD were classified  as immunoblastic 
lymphomas (28)  (Fig.  1 A). As depicted in Fig.  1 B, these 
lymphomas were positive for human CD20.  Immunohis- 
tochemistry staining with  mAb directed against human  K 
and  h  Ig L  chains  suggested tumor clonality  (e.g.,  tumor 
sample with  K Ig L  chain  negativity  [Fig.  1  C],  and  h  L 
chain  positivity  [Fig.  1  D]).  Organ  infiltration  of SCID 
mice bearing EBV-LPD by human cells was also confirmed 
by fluorescence in situ hybridization using probes specific 
for human X  and Y  chromosomes (e.g., human male cells 
infiltrating a mouse spleen,  [Fig.  1 E]).  These tumor- and 
organ infi trafing cells had a high expression of small EBV- 
encoded RNAs  (EBER-1  and EBER-2),  also  detected by 
in  situ  hybridization  (e.g.,  EBV  +  cells  infiltrating  mouse 
liver Fig. 1 b-). 
Animals  inoculated  intraperitoneally  developed  tumors 
in the abdominal cavity involving LN in the mesentery and 
porta hepatis,  the liver,  and spleen,  as well as the  thymus 
and mediastinal LN. Mice inoculated subcutaneously on the 
flank developed local tumors with subsequent extension of 
disease  to  the  retroperitoneal  space involving the  kidneys 
and then the liver and spleen. Occasionally, tumors metas- 
tasized to  axillary LN.  The  lymphomas detected  in  these 
organs were histologically and immunophenotipically iden- 
tical to those developing at the primary site of inoculation. 
Southern blot analysis  of the  fused termini  of EBV re- 
vealed emergence of the inoculated EBV DNA clones  in 
tumors recovered from SCID mice bearing human EBV- 
LPD (Table 1). In the case of donor 1, inoculation of EBV- 
LCL displaying two EBV  clones by analysis  of fused ter- 
mini  resuked  in  the  development  of tumors  bearing  the 
predominant  or  both  EBV  DNA  clones.  Southern  blot 
analysis  of the human Ig H  chain gene showed that these 
tumors  were  clonal.  In  the  case  of donor  2  EBV-LCL, 
EBV  termini  analysis  in  BamHI  and  EcoRI  digests  also 
showed a ladder  of fragments in  the  4.5-7-kb  size range, 
consistent  with  linear  replicating EBV  DNA  (29).  These 
fragments were present in tumors from only two mice in- 
oculated with  this  cell line.  A  MYC  gene  rearrangement 
was not detected in any of the tumors. 
Effect  of  Unstimulated  or  Nonspecifically  Activated  Effector 
Cells from  EBV-seropositive  Donors  on  the  Growth  of Autolo- 
gous EB V + Tumors in SCID Mice.  Our  previous  demon- 
stration  that  infusions  of PBMC  from  EBV-seropositive 
marrow donors could induce durable complete regressions 
of EBV-LPD in bone marrow graft recipients prompted us 
to explore the same strategy in the SCID mouse model. In 
these experiments, PBMC, IL-2-activated PBMC, purified 
T  cells,  and anti-CD3-activated T  cells,  derived from the 
same  EBV-seropositive  donors  with  high  EBV-specific 
CTLp used in subsequent experiments, failed to alter either 
the proportion of animals developing lethal autologous tu- 
mors or the time to death of affected animals (in vivo E/T 
ratio 2:1  to  1:1)  (data not shown).  These cell populations 
were predominantly CD3+CD4 + and displayed minimal in 
vitro cytotoxicity against the autologous EBV-LCL (<12% 
SL, E/T ratio 25:1). The anti-CD3-activated T  cells had a 
high expression ofT cell activation antigens. The IL-2-acti- 
vated  PBMC  showed  high  cytotoxicity  against  K562 
(>45% SL, E/T ratio of 25:1). Because we could not find 
any significant in vivo antilymphoma activity of unprimed 
or nonspecifically activated cell populations, we then inves- 
tigated whether T  cells specifically  stimulated with autolo- 
Table 1.  Molecular  Characteristics of Human EBV  + Lymphomas  in SCID Mice 
EBV-LCL inoculated 
EBV-LCL  EBV DNA  Ig H chain gene  Mouse 
EBV-LPD in SCID mice 
Tissue  EBV DNA  Ig H chain gene 
Donor 1  Clonal*  Rearranged 
Donor 2  Clonal~  Rearranged 
N1  Tumor  Clonal 
N2  Tumor  Clonal 
N19  Node  Clonal* 
N19  Thymus  Clonal* 
R1  Tumor  Clonal 
R3  Tumor  Clonal 
Rll  Tumor  Clonal 
$1  Tumor  Clonal 
$3  Tumor  Clonal 
$4  Tumor  Clonal 
$16  Tumor  ClonaF 
$17  Tumor  Clonal~ 














*Donor 1 EBV-LCL thymus, and LN from mouse N19 showed one major and one minor EBV DNA clone. 
*Evidence of EBV replication (both circular and linear forms detected). 
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Donor 1  Donor 2 
Purified T cells  EBV-CTL  Purified T cells  EBV-CTL 
CD3 (%)  88.8-93.7  95.6-98.5  87.3-95.9  94.3-98.8 
TCR-ot/]3 (%)  73.2-77.4  95.2-97.1  82.2-86.8  95.0-97.4 
TCR.-~/8 (%)  8.4-12.4  1.8-3.0  1.1-5.7  0.8-2.0 
CD4 (%)  51.9-59.1  1.1-21.3  61.8-69.0  10.2-13.9 
CD8 (%)  33.2-35.4  75.7-98.6  25.1-28.4  85.6-92.1 
CD56 (%)  2.0-5.1  < 1.5  1.5-3.2  <2.1 
CD25 (%)  2.3-10.2  48.1-68.2  4.8-16.0  50.2-83.2 
SL (%) 
(E/T ratio 6:1)*  ND  39.4-56.4*  ND  34.4--44.9* 
EBV-specific CTLp*  1/1,689  1/1255  1/4,752  1/255 
*Cytotoxicity against autologous EBV-LCL 
~EBV-specific T cell cytotoxicity and CTLp performed after 26 d in culture with autologons EBV-LCL 
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gous  EBV-LCL  could  alter  human  EBV-induced  lym- 
phomagenesis in the SCID mouse model. 
Characterization of EBV-specific  Cytotoxic  T  Lymphocytes 
Generated In  Vitro.  To generate EBV-specific CTL, puri- 
fied T  cells from normal EBV-seropositive individuals were 
stimulated with autologous EBV-LCL.  The characteristics 
of these  T  cells before and after 26  d  of culture are  pre- 
sented in Table 2.  For in vivo experiments, several sets  of 
EBV-specific CTL derived from two EBV-seropositive do- 
nors were used. As shown in Table 2, the T  cells generated 
in response to autologous EBV-LCL differed from the un- 
stimulated population in that there was a predominance of 
CD8 + cells, a high cytotoxicity against the autologous EBV- 
LCL,  and  a  markedly  higher  frequency  of EBV-specific 
CTLp. The responding cells were CD3 §  TCt<-o#I3  +, and 
CD16/CD56-.  These  cells  expressed  CDlla/CD18 
(LFA-1), CD58 (LFA-3), CD54 (ICAM-1), CD44, CD49d 
(VLA-c~4),  CD28,  and CD45R.O,  and were  negative for 
CD45RA, CD11b, CDllc, and CD80 (data not shown). 
The cytotoxicity assays presented in Fig. 2  illustrate the 
selective cytotoxic profile of two EBV-specific CTL lines 
used in in vivo experiments after 26 d in culture. As shown 
in Fig.  2  A,  CTL derived from  donor  1  showed  marked 
cytotoxicity against the  autologous EBV-LCL,  intermedi- 
ate  cytotoxicity against EBV-LCL  sharing the  allele A2.2 
with the autologous EBV-LCL, and no SL against autolo- 
gous EBV- activated B cells or K562. In Fig. 2 B, the cyto- 
Figure 2.  Cytotoxicity profile of EBV-specific T cells. (A) Cytotoxic 
activity of donor 1 EBV-specific  T cells stimulated  in vitro with the au- 
tologous EBV-LCL for 26 d. There was high SL of the autologous EBV- 
LCL (HLA type: A1,2.2; B44.1,62.3; DR4,7), intermediate cytotoxicity 
of an EBV-LCL shanng only A2.2 with the autologous EBV-LCL, and 
no SL of autologous EBV- activated B cells or K562 cell line. (B) Cyto- 
toxic activity  of donor 2 EBV-specific T cells stimulated  in vitro with the 
autologous EBV-LCL for 26 d. There was high cytotoxicity against the 
autologous EBV-LCL (HLA type: A1,3.2; B7.2,8; DR3,4), low cytotox- 
icity of target EBV-LCL sharing  HLA A1 and DR4 (donor 1 EBV-LCL) 
and HLA B7.2 with the autologous  EBV-LCL, and no SL of autologous 
EBV  activated  B cells or K562 cell line. Results are presented as mean 
SL of triplicate parallel  cultures  for each E/T ratio in standard 4-h 5~Cr re- 
lease assays. 
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Figure 3.  Inhibition ofcytotoxicity of EBV specific T  cells. Before the 
coincubation period in standard 4-h SlCr release assays, effector or target 
cells were incubated separately for 1 h  with the indicated concentrations 
of anti-CD3  or  anti-TCR-ot/J3  mAb  (EBV-specific  T  cells),  or  with 
anti-HLA-A,B,C  or  anti-HLA-DR,DP,DQ  mAb  (EBV-LCL).  In  the 
experiment shown, EBV-specific T  cells from donor 2 stimulated in vitro 
for 26  d  with the autologous EBV-LCL were used. The percentage of 
CD4 and CD8 T  cells was, respectively, 12.5 and 85.2%. The addition of 
anti-CD3 or anti-TCR-ct/[3 mAb inhibited almost completely the cyto- 
toxicity against the autologous EBV-LCL Addition of anti-HLA-A,B,C 
mAb inhibited SL to a higher degree than anti-HLA-DR,DP,DQ mAb, 
suggesting the predominance of HLA class I-restricted CTL. Results are 
presented as mean SL of triplicate parallel cultures for each antibody con- 
centration at an E/T ratio of 10:1. 
toxicity profile ofEBV-specific CTL derived from donor 2 
is depicted. Again, there was a high SL against  the autolo- 
gous EBV-LCL and intermediate lysis of two EBV-LCLs, 
one sharing the  HLA alleles  A1  and DR4  and the  other 
HLA-B7.2, with  the  autologous EBV-LCL.  Once  again, 
there was virtually no cytotoxicity against autologous EBV- 
activated B cells or K562 cell fine. 
The assay presented in Fig. 3 shows mAb-mediated inhi- 
bition of cytotoxicity of an EBV-specific CTL line derived 
from donor 2  after 26  d  in  culture  with  the  autologous 
EBV-LCL (E/T ratio 10:1;  CD4 +,  12.5%;  CD8 +, 85.2%). 
As shown,  SL of autologous EBV-LCL was almost totally 
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Figure  4.  Survival of SCID mice inoculated intraperitoneally with 107 
donor 1 or donor 2 EBV-LCL and randomized to be treated intraperito- 
neally on day 4 with 10  v donor 1 EBV-specific T  cells  (26 d in culture). 
Mice were treated intraperitoneally with u-asialo GM1 on days -1,  +4, 
+8, and every 5-7 d  thereafter.  Only mice inoculated with the autolo- 
gous EBV-LCL responded to  the infusion of EBV-specific T  cells,  and 
two to five treated animals never developed EBV-LPD. 
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inhibited by coincubation with anti-CD3 or anti-TCP,.-0t/13 
mAb and largely abrogated by the addition of anti-HLA- 
A,B,C mAb. Anti-HLA-DR,DP,DQ mAb partially inhib- 
ited the cytotoxicity against  autologous EBV-LCL, poten- 
tially reflecting the presence ofEBV-specific CD4 + CTL. 
Effect  of EBVospecific  CTL  Administered  Intraperitoneally 
into SCID Mice Bearing Autologous  or Allogeneic Intraperitoneal 
EBV + Lymphomas.  In the experiment depicted in Fig.  4, 
SCID  mice  were  inoculated  intraperitoneally  with  107 
EBV-LCL derived from either of two normal EBV-sero- 
positive  donors  and  were  randomized  either  not  to  be 
treated (n  =  10) or to receive 107 EBV-specific CTL de- 
rived from donor 1 intraperitoneally 4 d later (n =  5). Al- 
though these donors shared HLA-A1 and DR4, there was 
tittle cytotoxicity against EBV-LCL from donor 2 by EBV- 
specific CTL derived from donor 1 (10.6% SL, E/T ratio 
25:1). As shown in Fig. 4, SCID mice inoculated intraperi- 
toneally with  107 EBV-LCL alone survived a  median  of 
23-26 d, and all had died of lymphomas by day 32. SCID 
mice inoculated with EBV-LCL from donor 2  that were 
treated on day 4 with EBV-specific CTL derived from do- 
nor  1  also  all  died of EBV-LPD  by day 27.  In  contrast, 
SCID mice inoculated with EBV-LCL from donor 1 and 
subsequently  treated  with  autologous  EBV-specific  CTL 
survived a median of 112 d  (P <0.001).  Of these animals, 
two  of five survived long term without  ever developing 
lymphomas.  Nevertheless,  despite  the  significantly  im- 
proved survival,  three  of five mice  receiving autologous 
CTL ultimately died of EBV-LPD after day 75, suggesting 
that,  in these animals,  inoculation of a single  dose of 107 
EBV-specific CTL (in vivo E/T ratio  1:1)  delayed rather 
than  prevented  the  development  of EBV-LPD.  Similar 
findings  were  obtained  with  EBV-specific  CTL  derived 
from donor 2 against  autologous but not donor I--derived 
EBV-LPD (data not shown). 
Effect of EBV-specific  CTL Administered Intravenously  into 
SCID Mice Bearing Intraperitoneal or Subcutaneous EB V + Tu- 
mors.  Thereafter, we investigated whether the infusion of 
these  putative  EBV-specific  and  HLA-restricted effectors 
by the intravenous route would also mediate a therapeutic 
effect.  The  intravenous  inoculation  of 10  v EBV-specific 
CTL resulted in improved survival of SCID mice inocu- 
lated intraperitoneally with autologous EBV-LCL (n =  5)  (P 
<0.001), relative to untreated animals (n =  10) (Fig.  5 A). 
However, in  contrast  to  animals  treated intraperitoneally 
with EBV-specific CTL, all mice died of EBV-LPD. 
Since  the  vast  majority  of the  responding  CTL  were 
CD3+CD8+TCR-(x/I  3+ and expressed CD25, we hypoth- 
esized that, in the intraperitoneal EBV  + SCID mouse model, 
these cells might require IL-2 support for prolonged in vivo 
survival. Accordingly, in a subsequent experiment using a 
second  set  of EBV-specific  CTL  derived from the  same 
EBV-seropositive donor (26 d in culture), SCID mice in- 
oculated intraperitoneally with 107 EBV-LCL were divided 
into three groups. Mice in group 1 were left untreated (n = 
5). The second group (n =  5) was treated with a low dose 
oflL-2 alone for 14 d. The third group (n =  5) was treated 
with the same dose of IL-2 and also  received 107 autolo- A  100 
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Figure 5.  (.4) Survival of SCID mice inoculated intraperitoneally with 
107 donor 2 EBV-LCL and randomized not to be treated  (~)  or to re- 
ceive 107 autologous EBV-specific T  cells (26 d in culture) intravenously 
on day 4. Mice were also treated with ~x-asialo GM1 intraperitoneally on 
days -1,  +4,  +8,  and every 5-7 days thereafter. EBV-specific T  cell- 
treated mice had a significantly improved survival relative to the group of 
untreated animals. (B) Survival of SCID mice inoculated intraperitoneally 
with 107 donor 2 EBV-LCL and randomized not to be treated (O), to re- 
ceive IL-2 alone (2,500 IU i.p. twice daily for 14 d), or IL-2 and 107 au- 
tologous EBV-specific T  cells  (26  d  in culture) intravenously on day 4. 
Mice were treated intraperitoneally with c~-asialo GM1 on days -1,  +4, 
+8, and every 5-7 d thereafter. CTL plus IL-2-treated animals had a sig- 
nificantly  prolonged  survival  relative  to  untreated  animals  or  animals 
treated with IL-2 alone, of five animals treated with CTL and IL-2, two 
never developed EBV-LPD. 
gnus EBV-specific CTL intravenously on day 4 after EBV- 
LCL  inoculation.  As  shown  in  Fig.  5  B,  all  animals  in 
groups  1 and 2  died oflymphoma by days 31  and 40,  re- 
spectively. Survival in group 3 was significantly prolonged 
relative to mice in group 2  (P =  0.004).  Three of five ani- 
mals  in  this  group  ultimately  succumbed  to  lymphomas, 
but onset was delayed, with deaths at days 59,  115, and 130 
after EBV-LCL inoculation. Two animals never developed 
EBV-LPD. 
In subsequent experiments, we used an alternative animal 
model in which EBV-LCL were inoculated subcutaneously 
rather than intraperitoneally into  SCID mice and investi- 
gated whether the intravenous administration of EBV-spe- 
cific  CTL  could  mediate  regressions  of well-established 
EBV-LPD.  In the  experiment depicted in  Fig.  6,  animals 
bearing large  subcutaneous  tumors  (median  mean  surface 
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Figure 6.  Survival of SCID mice inoculated subcutaneously with 20 ￿ 
106 EBV-LCL and randomized not to be treated  (~),  or to receive IL-2 
alone (2,500 IU i.p. twice daily for 14 d) on day 35, 107 autologous EBV- 
specific T  cells (26 d in culture) intravenously, or the combination of IL-2 
and CTL. Mice were treated intraperitoneally with ot-asialo  GM1 on days 
-1,  +4,  +8,  and every 5  to  7  days thereafter.  Both CTL- and CTL- 
plus-IL-2-treated animals had a significantly improved survival relative to 
untreated animals or SCID mice treated with IL-2 alone. 
treated intravenously 35 d after EBV-LCL inoculation with 
autologous 107 EBV-specific CTL with or without IL-2, as 
above.  There  were  tumor  regressions  over the  following 
12-24  d  in the  two groups of animals treated with  CTL, 
whereas untreated mice and those treated with IL-2 alone 
had progressive tumor growth and extension of disease  to 
the  abdominal  cavity, ultimately causing the  death  of the 
animals.  CTL-treated mice had improved survival relative 
to  control animals  (CTL,  P  =  0.004;  CTL  +  IL-2, P  -- 
0.02).  All  mice  treated  with  CTL and  four  of five mice 
treated with CTL plus IL-2 had regressions of subcutane- 
ous tumors. Ultimately, three animals in each group died of 
EBV-LPD  during  the  course  of  tumor  regression.  At 
necropsy, these mice had extensive abdominal disease.  Stil], 
two of five mice in each group had complete tumor regres- 
sions  and  survived  >5  mo  after  CTL  treatment.  At  day 
200, the surviving four animals were killed, and full necrop- 
sies were performed. Although one mouse treated with CTL 
alone had complete regression of the subcutaneous tumor, 
kidney infiltration by tumor cells was still detected. Impres- 
sively,  the  tumor  was  infiltrated  by  human  CD45RO § 
cells,  demonstrating the persistence  of human  activated T 
cells infiltrating the EBV + tumor >5 mo after intravenous 
adoptive transfer of EBV-specific T  cells (data not shown). 
The other three animals had no evidence of EBV-LPD. 
In  Vivo  Tracking and Activity of EBV-specific CTL in SCID 
Mice Bearing Both Autologous and Allogeneic EBV + Subcutane- 
ous Tumors.  To evaluate homing of the  CTL population 
to subcutaneous tumor sites, we labeled these EBV-specific 
effector cells with a lypophilic fluorescent dye, PKH26.  In 
preliminary experiments, we determined the optimal con- 
centration and time of incubation  of PKH26 for maximal 
nontoxic membrane binding. Incubation with 10 ~zM PKH26 
for 2 rain resulted in a homogeneous bright staining of the 
EBV-specific CTL population,  without loss of viability or 
cytotoxicity (data not shown). Also, in preliminary experi- 
ments,  EBV +  lymphoma-hearing mice were  given  either 
T Cell Immunotherapy of Human EBV + Lymphomas in the SCID Mouse Figure  7.  Early  preferential localization of PKH26-1abeled EBV-spe- 
cific CTL to the autologous rumor in SCID mice bearing both the autol- 
ogous and HLA-mismatched EBV  § tumors. (A) HLA-mismatched EBV  § 
tumor showing only background autofluorescence. ￿  (B) Autologous 
EBV  § tumor on the same mouse infiltrated by PHK26-1abeled  EBV-spe- 
cific T cells. ￿  (C) Higher magnification of B showing the morphol- 
ogy of the infiltrating cells. ￿  90. 
no treatment or an intravenous infusion of PKH26-1abeled 
autologous EBV-specific CTL. After 24 h, the animals were 
killed and sections of the tumors were analyzed by fluores- 
cence  microscopy.  Infiltration  of EBV +  tumors by labeled 
CTL  was  documented,  whereas  tumors  of untreated  ani- 
mals  only  showed  background  autofluorescence  (data  not 
shown).  In subsequent experiments,  107 autologous PKH26- 
1223  Lacerda et al. 
labeled CTL were adoptively transferred intravenously 33 d 
after  inoculations  of EBV-LCL  into  SCID  mice  bearing, 
on  opposite  flanks,  both  autologous  and  fully  HLA-mis- 
matched  subcutaneous  EBV §  tumors  against  which  there 
was no cytotoxicity in vitro. After 24 h, animals were sacri- 
ficed,  and  snap-frozen  sections  were  analyzed  by  fluores- 
cence microscopy. While  HLA-mismatched EBV §  tumors 
exhibited  some  background  autofluorescence,  very  few 
bright signals could be discerned  (Fig. 7 A). In contrast,  the 
autologous tumors in the same animals exhibited numerous 
bright  fluorescent  signals  (Fig.  7  B)  which,  on  a  higher 
magnification,  could  be  discerned  as  infiltrating  labeled 
cells (Fig.  7  C).  Immunohistochemistry  studies of the sam- 
ple  depicted  in  Fig.  7  confirmed  the  presence  of human 
CD45RO +  cells  in  the  autologous  but  not  in  the  HLA- 
mismatched  EBV +  lymphoma  (data  not  shown).  In  sepa- 
rate  identical  experiments,  EBV-specific  CTL  from  each 
donor showed the same selective pattern of infiltration. 
To further  confirm the preferential  infiltration  of EBV- 
specific  CTL  into  EBV +  lymphomas  bearing  appropriate 
HLA determinants,  six animals bearing large subcutaneous 
EBV +  tumors in each flank,  one  derived from the autolo- 
gous  (donor  2)  and  the  other  from  an  HLA-mismatched 
donor,  were  randomized  to  be  treated  or not  with  EBV- 
specific CTL derived  from donor  2  on  day 33,  which  ex- 
hibited  strong cytotoxicity in vitro  against  autologous  and 
no SL of the HLA-mismatched EBV-LCL.  Mice were also 
infused  intraperitoneally  with  5,000  IU  IL-2  every  other 
day,  for a  total  of four  doses.  Only  autologous  tumors  re- 
sponded  to  the  CTL infusion,  whereas  mismatched EBV + 
tumors of CTL-treated animals and both tumors of control 
animals continued  to grow.  7-14  d  after adoptive intrave- 
nous  transfer  of 107  EBV-specific  CTL,  the  mean  surface 
area  of autologous  EBV  +  tumors  decreased  by  40-60%. 
The  autologous  tumors  remained  confined  to  the  original 
site of inoculation,  whereas mismatched tumors were larger 
(140-200%)  and  infiltrated  the  abdominal  cavity,  eventu- 
ally  causing  death  of the  animals.  7  d  after adoptive  CTL 
transfer,  single-cell  suspensions  of autologous  and  HLA- 
mismatched  tumors  from two  of the  CTL-treated  animals 
revealed preferential infiltration  of the autologous  subcuta- 
neous  tumor  by human  CD3 +  cells.  Very  few  human  T 
cells were found infiltrating the HLA-mismatched subcuta- 
neous  tumors  or  in  peritoneal  washes  containing  human 
CD45 +  cells,  directly  invading  the  peritoneal  cavity from 
the HLA-mismatched subcutaneous  tumor  (necropsy find- 
ing)  (data not shown). A  similar experiment was performed 
using donor  1 EBV-specific T  cells,  and  CD3+CD8+CD4 - 
cells  were  detected  infiltrating  only the  autologous  EBV + 
tumor 14 d after adoptive transfer (data not shown). 
To further analyze the in vivo selectivity of EBV-specific 
T  cell  homing,  two  SCID  mice  were  inoculated  in  the 
right  flank  with  donor  1  EBV-LCL  (HLA  type:  A1,2.2; 
B44.1,62.3;  DR4,7)  and  in  the  left  flank  with  an  EBV- 
LCL derived from a genotypically HLA haplotype--sharing 
related  donor  (HLA  type:  A1,31;  B27.5,44.1;  DR.4,7). 
These EBV-LCL also shared  an additional  HLA-DR  anti- 
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Figure  8.  Preferential infiltration of the  subcutaneous autologous 
EBV  +  tumor  in  mice bearing both  the  autologous  (HLA-A1,2.2; 
B44.1,62.3; DtL4,7) and an HLA haplotype-sharing genotipically related 
EBV  § tumor  (HLA-A1,A31;  B27.5,44.1; DR4,7).  14 d after adoptive 
transfer of EBV-specific T  cells, human CD45bnghtCD3+HLA-DR  + 
CD4-CD8  + cells were detected infiltrating predominantly the autolo- 
gous subcutaneous EBV  + tumor (right) (6.4%), whereas very few T cells 
(0.6%) were detected  infiltrating the  haplotype-sharing subcutaneous 
EBV  + tumor (/eft). The lymphoma cells were HLA-D/L+CD3  -. Each dot 
blot represents the fluorescence  intensity of 5,000 gated cells. 
At day 45, the animals were treated intravenously with 107 
and intraperitoneally with 2  ￿  106 donor 1 EBV-specific T 
cells cultured in the presence of the autologous EBV-LCL 
for 33  d.  In vitro,  the  cytotoxicity of these  effector  cells 
against  the  autologous  EBV-LCL,  the  haplotype-sharing 
EBV-LCL, an HLA-mismatched EBV-LCL, and K562 was, 
respectively,  44,  28,  3,  and 0%  (E/T  ratio  5:1).  Mice also 
received 5,000 IU IL-2 every other day for a total of four 
doses.  Over the next  10 d, regressions were observed only 
in donor 1 tumors (20-30% decrease in mean surface area). 
Flow cytometry analysis of both tumors 14 d after adoptive 
T  cell  transfer  revealed an  -'~10-fold higher infiltration  of 
the  autologous  tumor  by  human  T  cells,  relative  to  the 
haplotype-sharing EBV  §  tumor.  The human lymphocytes 
infiltrating  the  tumor  were  CD45b~ghtCD3+HLA-DR  § 
and,  predominantly,  CD4-CD8 +.  The  EBV  §  lymphoma 
cells were HLA-DtL+CD3  -.  Data from one  of these  ani- 
mals  are  represented  in  Fig.  8.  In this  case,  6.4%  human 
CD3 § cells were detected infiltrating the autologous EBV + 
tumor versus 0.6% infiltrating the haplotype-matched EBV  § 
tumor. 
Discussion 
As  originally  demonstrated  by  Mosier  et  al.  (20),  and 
confirmed  in  this  and  other  reports  (22,  23,  25),  SCID 
mice inoculated with PBL from EBV-seropositive  donors 
or with  human EBV-transformed  B  cell  lines  rapidly de- 
velop lethal human EBV-induced lymphoproliferations with 
characteristics  similar  to those  arising in  immunocompro- 
raised patients. Recently, several groups have used this pre- 
clinical model to explore  the potential  of gamma globulin 
(30),  mAbs directed  against human CD21,  CD23,  CD24, 
and  CD40  B  cell  antigens  (31-33),  low  dose  IL-2 treat- 
ment  (34),  and  imexon  (35)  in  the  treatment  of human 
EBV-induced lymphoproliferations developing in the SCID 
mouse. 
To date, only two studies have examined the cellular ef- 
fects  of adoptively transferred  human lymphocytes in  this 
xenograft model.  In  1993,  Boyle et  al.  (36)  reported  that 
adoptive  intraperitoneal  transfer  of autologous  EBV-spe- 
cific  CTL prolongs the  survival of SCID mice inoculated 
intraperitoneally with EBV-LCL. R.encher et al.  (37)  then 
reported that concomitant intraperitoneal administration of 
CD8 + but not CD4 §  EBV-specific T  cells  could decrease 
the incidence of abdominal EBV + tumors after intraperito- 
neal inoculation of a small number of EBV-LCL. Neither 
of these  studies  used  SCID  mice  pretreated  to  abrogate 
their  NK  cell function.  Furthermore,  R.encher  et  al.  (37) 
did  not show whether  treatment  with  T  lymphocytes re- 
suited in a survival advantage. 
This  report  confirms these  observations  and documents 
several new findings of potential significance to our under- 
standing of the response of EBV-induced lymphoprolifera- 
tions to adoptive immunotherapeutic  approaches.  For our 
experiments,  C.B-17  scid/scid  mice  treated  with  o~-asialo 
GM1 were used to ensure suppression of endogenous asialo 
GMl-expressing  NK  cells.  Several  investigators  have 
shown that BALB/c  nu/nu  (nude)  and SCID mice treated 
with (x-asialo  GM1 have lower NK cell function and higher 
engraftment  of murine  tumors,  human  PBL,  and  human 
tumors (24, 38, 39). In a separate series of experiments,  we 
demonstrated that inoculation  of as few as 5  ￿  104 EBV- 
LCL induced lethal tumors in 40-100% ofo~-asialo GM1- 
treated  SCID  mice  (depending  on  the  EBV-LCL  tested) 
(25). At higher cell doses, all ol-asialo GMl-treated animals 
died  of EBV §  lymphomas,  with  duration  of survival  in- 
versely proportional to the dose of EBV-LCL administered 
(25). At higher doses than were used in vivo, oL-asialo GM1 
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hibit  CTL cytotoxicity against  the  autologous  EBV-LCL 
(data not shown).  Accordingly, we adopted this model in 
our studies of adoptive cell therapy to abrogate endogenous 
NK cell function, which might otherwise contribute to the 
therapeutic responses observed. 
Taken  together,  our  studies  failed  to  demonstrate  any 
significant  in  vivo  activity  of adoptively  transferred  un- 
primed or nonspecifically activated cell populations against 
EBV-LPD developing in xenografted SCID mice. Murphy 
et al. (38) found a higher prevalence of EBV-LPD in SCID 
mice inoculated  with  a  human  colon  carcinoma cell line 
and  treated  with  anti-CD3-activated  PBL  from  EBV- 
seropositive donors, which may suggest that nonspecifically 
activated T  cells might contribute to rather than act against 
the  development  of EBV-LPD  in  the  hu-PBMC-SCID 
mouse model. In our marrow allograft recipients, a striking 
increase in the number of circulating EBV-specific CTLp 
within 2 wk after their administration has been documented 
(12),  reflecting either a massive proliferation of the EBV- 
specific CTL infused or their recruitment from the donor 
bone marrow-derived T  cells developing within the trans- 
formed host's  environment.  In  our  SCID  mouse  model, 
recruitment of additional effectors is unlikely.  In addition, 
whereas  it  remains  to  be  determined  whether  the  small 
number ofEBV-specific CTLp infused in the unprimed or 
nonspecifically  activated  cell  populations  can  expand  in 
the SCID mouse microenvironment, any expansion would 
likely be limited. 
In subsequent  experiments,  we investigated whether  T 
cells  specifically  stimulated  with  autologous  EBV-LCL 
could  alter  EBV*  lymphomagenesis in  the  SCID  mouse 
model.  The T  cells  generated in vitro were EBV specific, 
HLA  restricted,  and  predominantly  of CD8  phenotype. 
The addition of anti-HLA class I mAb markedly inhibited 
cytotoxicity against  autologous EBV-LCL,  suggesting  the 
predominance  of HLA  class  1-restricted  CD8 +  T  cell- 
mediated cytotoxicity in the responding T  cell population. 
In vivo, only CD8 + cells were found infiltrating the autol- 
ogous EBV  + tumors by cytofluorometry (Fig.  8), suggest- 
ing that they were important effectors in the observed re- 
sponses.  In  SCID  mice  inoculated  intraperitoneally  with 
EBV-LCL,  adoptive  transfer  of EBV-specific  CTL intra- 
peritoneally at the same cell dose used in previous in vivo 
studies with unsensitized effectors (107 cells) resulted in im- 
proved survival only of animals bearing autologous intra- 
peritoneal tumors. Mice bearing partially mismatched EBV + 
tumors, against which there was virtually no. in vitro cyto- 
toxicity, did not respond, suggesting also an HLA-restricted 
activity in  vivo.  Similar results were  obtained with  CTL 
propagated from the blood of each of the donors used. 
We then investigated whether EBV-specific CTL given 
intravenously could also induce tumor regression in SCID 
mice bearing intraperitoneal EBV-LPD, since this route of 
effector cell administration would be more comparable to 
that  used  clinically  (10,  13,  14).  In  these  experiments, 
treated  mice  had  improved  survival relative  to  untreated 
animals.  Nonetheless,  all  animals ultimately died of EBV- 
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LPD  and  after a  shorter interval than  those  treated intra- 
peritoneally. In interpreting these results,  we considered two 
possibilities: first,  that the intravenously administered effec- 
tors did not survive in sufficient numbers to protect the an- 
imals or, alternatively, that their homing to intraperitoneal 
tumor sites  was  impaired.  To  address  the  first possibility, 
we examined the effects of administering IL-2 at low doses 
for 14 d after infusions of effector cells. As shown in Fig. 5 
B,  IL-2 alone  had little  effect on the  survival of o~-asialo 
GMl-treated mice inoculated intraperitoneally with EBV- 
LCL. This result is similar to that reported by Baiocchi and 
Caligiuri (34),  who observed that IL-2 treatment of SCID 
mice  inoculated  intraperitoneally  with  PBL  from  EBV- 
seropositive individuals  did not prevent lymphomagenesis 
if mice were also treated with ot-asialo  GM1.  In contrast, 
the survival of animals that received an intravenous infusion 
of EBV-specific CTL and IL-2 was comparable to that of 
animals given an intraperitoneal injection of effectors with- 
out IL-2. In both groups, two of five animals never devel- 
oped EBV-LPD. Thus, in this intraperitoneal EBV + tumor 
SCID  mouse  model,  concomitant  administration  of IL-2 
appears to have resulted in a survival advantage relative to 
mice treated with EBV-specific T  cells alone. 
In  subsequent  experiments,  we  also  demonstrated  that 
intravenous  administration  of 107  EBV-specific  CTL  in- 
duced  regressions of large EBV  +  subcutaneous  tumors,  at 
an in vivo E/T ratio no greater than  1:100.  In contrast to 
animals bearing  intraperitoneal  EBV +  tumors  and  treated 
intravenously with EBV-specific CTL alone, mice bearing 
subcutaneous  tumors  had  complete  regressions  of EBV- 
LPD after one infusion of EBV-specific CTL and survived 
long term, even in the absence of exogenous IL-2 support. 
In vitro, the EBV-specific T  cells used for adoptive im- 
munotherapy exhibited HLA-restricted cytotoxicity. In vivo, 
this restricted activity was manifested not only by preferen- 
tial regression of autologous EBV  + tumors, but also by pref- 
erential homing and selective CTL infiltration of  these tumors. 
In animals beating both the autologous and HLA-mismatched 
EBV  + tumors, PKH26-1abeled CTL homed within 24 h of 
adoptive intravenous transfer to the autologous but not to 
HLA-mismatched tumors. Immunohistochemistry and cyto- 
fluorometry studies  also  detected EBV-specific  CTL infil- 
trating the autologous but not HLA-mismatched EBV + tu- 
mors up to 14 d after their infusion (data not shown). 
In the experiment shown in Fig. 8, although the autolo- 
gous EBV-specific T  cells lysed in vitro the HLA genotyp- 
ically  haplotype-identical  related  EBV-LCL,  albeit  to  a 
lesser degree than the  autologous EBV-LCL (12-17% less 
SL  for  all  the  dilutions  tested),  very few  human  T  cells 
were detected infiltrating the haplotype-identical EBV + tu- 
mor. This degree of preferential infiltration of the autolo- 
gous  tumors by autologous EBV-specific T  cells  may re- 
flect differences in the frequencies  of EBV-specific CTLp 
recognizing specific EBV antigens in the  context of HLA 
class I determinants uniquely  expressed on the  autologous 
rather than on the haplotype-matched EBV  +  tumor cells. 
Murray et al.  (40)  and Khanna et al.  (41)  have shown that 
whereas certain EBV antigens such as EBV nuclear antigen (EBNA) 3A, 3B, and 3C may be recognized by EBV-spe- 
cific T  cells upon presentation  by a variety of HLA class I 
antigens,  others,  such  as  latent  membrane  protein  2  and 
EBNA  2,  are  preferentially  associated  with  specific  HLA 
class I molecules.  Further studies using EBV-specific T  cell 
clones of defined HLA restriction will be required to clarify 
this issue. 
Studies  investigating the specific activity of tumor infil- 
trating lymphocytes (TIL), CTL, and LAK cells  in murine 
models have also shown that these cells  can selectively mi- 
grate  to  and  infiltrate  a  sensitizing  tumor,  as  opposed  to 
normal surrounding tissue (8, 42, 43). However, Wallace et 
al.  (44)  did  not  find preferential  homing of PKH-labeled 
TIL to autologous versus nonautologous tumors or normal 
lung tissue,  despite having a specific in vivo activity against 
the autologous tumor. Kast et al.  (45) have also shown that 
adenovirus  antigen-specific  murine  T  cells  from C57B1/6 
(B6)  mice will selectively induce regressions  of adenovirus 
(Ad) type 5 E1A/E1B-induced B6 tumors, but not ofAd 5 
E1A/1B-induced BALB/c tumors in B6 mice bearing both 
the  B6  and  BALB/c  tumor,  indicating  their  H-2  restric- 
tion.  Similarly, when Crowley et al.  (46) tested the in vivo 
activity of human CTL in a xenograft nude mouse model 
of human melanoma, mice bearing HLA-A2 hepatic mela- 
noma metastases had a reduction in the number of metastases 
only after  treatment  with  HLA-A2-restricted  melanoma- 
specific CTL but not with infusions ofHLA-A11-restricted 
melanoma reactive CTL.  In neither of these studies,  how- 
ever, were the homing characteristics  of the infused effec- 
tors examined. 
The mechanisms by which small numbers of T  cells  in- 
duce regressions of large tumors, as observed in this model, 
and more dramatically in initial clinical reports (10), are cur- 
rently unknown.  In murine models, both cytotoxic CD8 + 
and noncytotoxic CD4 + and CD8 + TIL that generate cy- 
tokines, particularly IFN-~/and TNF, have been implicated 
in tumor regression (47). These regressions were T  cell de- 
pendent and tumor specific. In our studies, the selective re- 
gression ofautologous tumors in animals bearing both autol- 
ogous and allogeneic tumors does not preclude the possibility 
that EBV-specific T  cells  selectively infiltrating the autolo- 
gous tumors induce regressions by the release of locally ac- 
tive cytokines, but do argue against the induction of tumor 
regression by the nonspecific activity of cytokines released 
into  the  general  circulation.  Experiments  to  address  these 
questions in the informative SCID mouse models described 
in this study are currently in progress. 
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